Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice

Transfusion

Volumn 53, Issue 4, 2013, Pages 888-901

  Vamvakas, Eleftherios C ^a  

^a not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; APHERESIS; BLOOD COMPONENT; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL PRACTICE; DISEASE TRANSMISSION; DONOR SELECTION; ERYTHROCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; PLASMA; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE; TREATMENT PLANNING;

EID: 84876109867     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03825.x     Document Type: Review

References (98)

1. Kuhn TS,. The function of measurement in modern physical science. Isis 1961; 52: 161-93.
2. Kuhn TS,. The structure of scientific revolutions. Chicago (IL): University of Chicago Press; 1962.
3. Farrugia A,. Falsification or paradigm shift? Toward a revision of the common sense of transfusion. Transfusion 2011; 51: 216-24.
4. Popovsky MA,. Multicomponent apheresis blood collection in the United States: current status and future directions. Transfus Apher Sci 2005; 32: 299-304.
5. Popovsky MA,. Transfusion-related acute lung injury: incidence, pathogenesis and the role of multicomponent apheresis in its prevention. Transfus Med Hemother 2008; 35: 76-9.
6. Vamvakas EC,. Causes of mortality related to allogeneic blood transfusion. In:, Vamvakas EC,. Decision-making in transfusion medicine. Bethesda (MD): American Association of Blood Banks; 2011. p. 31-85.
7. Zimrin AB, Hess JR,. Current issues relating to transfusion of stored red blood cells. Vox Sang 2009; 96: 93-103.
8. Lelubre C, Piagnerelli M, Vincent JL,. Association between storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion 2009; 49: 1348-64.
9. Vamvakas EC,. Meta-analysis of clinical studies of the purported deleterious effects of "old" (versus "fresh") red blood cells: are we at equipoise? Transfusion 2010; 50: 600-10.
10. van de Watering L,; for the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Pitfalls in the current published observational literature on the effects of red blood cell storage. Transfusion 2011; 51: 1847-54.
11. Arduino MJ, Bland LA, Tipple MA, Aguero SM, Favero MS, Jarvis WR,. Growth and endotoxin production of Yersinia enterocolitica and Enterobacter agglomerans in packed erythrocytes. J Clin Microbiol 1989; 27: 1483-5.
12. Centers for Disease Control and Prevention. Update: Yersinia enterocolitica bacteremia and endotoxin shock associated with red blood cell transfusion-United States, 1991. MMWR Morb Mortal Wkly Rep 1992; 40: 176-8.
13. Kehler MR, Masuno T, Moore EE, Damle S, Meng X, Song Y, Liang X, Niedzinski J, Geier SS, Khan SY, Gamboni-Robertson F, Silliman CC,. Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood 2009; 113: 2079-87.
14. Schmidt M,. Comparison of different methods of bacterial detection in blood components. ISBT Sci Ser 2009; 4: 80-6.
15. Kleinman S, Dumont LJ, Tomasulo P, Bianco C, Katz L, Benjamin RJ, Gajic O, Brecher ME,. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion 2009; 49: 903-12.
16. Kerkhoffs JLH, Eikenboom JC, Schipperus MS, van Wordragen-Vlaswinkel RJ, Brand R, Harvey MS, de Vries RR, Barge R, van Rhenen DJ, Brand A,. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108: 3210-15.
17. FDA/CBER. Fatalities reported to the FDA following blood collection and transfusion. Annual summary for fiscal year 2010. [cited 2012 Jul 11]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ ReportaProblem/TransfusionDonationFatalities/UCM254802.htm
18. Vamvakas EC,. The ethics of wasting the donor's gift of buffy coat. Vox Sang 2011; 100: 256-7.
19. Vamvakas EC,. Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009; 49: 2743-58.
20. Vamvakas EC, Blajchman MA,. Transfusion-related mortality: the on-going risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113: 3406-17.
21. Vamvakas EC, Blajchman MA,. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24: 77-124.
22. Leiss W, Tyshenko M, Krewski D,. Men-having-sex-with-men donor-deferral risk assessment: an analysis using risk-management principles. Transf Med Rev 2009; 23: 85-102.
23. AuBuchon JP, Birkmeyer JD, Busch MP,. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127: 904-9.
24. Hofmann A, Farmer S, Shander A,. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist 2011; 16 (Suppl 3): 3-11.
25. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR,. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010; 50: 753-65.
26. Shander A, Hofmann A, Gombotz H, Theusinger OM, Spahn DR,. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007; 21: 271-89.
27. Schrezenmeier H, Seifreid E,. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99: 1-15.
28. Greinacher A, Fendrich K, Brzenska R, Kiefel V, Hoffmann W,. Implications of demographics on future blood supply: a population-based cross-sectional study. Transfusion 2011; 51: 702-9.
29. Spahn DR, Moch H, Hofmann A, Isbister JP,. Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology 2008; 109: 951-3.
30. Shander A,. Surgery without blood. Crit Care Med 2003; 31 (Suppl 12): S708-14.
31. Frenzel T, van Aken H, Westphal M,. Our own blood is still the best thing to have in our veins. Curr Opin Anaesthesiol 2008; 21: 657-63.
32. Waters JH, editor. Blood management: options for better patient care. Bethesda (MD): American Association of Blood Banks; 2008.
33. Waters JH, Shander A, editors. Perioperative blood management: a physician's handbook. 2nd ed. Bethesda (MD): American Association of Blood Banks; 2009.
34. Becker J, Shaz B,. Guidelines for patient blood management and blood utilization. Bethesda (MD): American Association of Blood Banks; 2011.
35. Waters JH, Dyga RM, Yazer MH,. Guidelines for blood recovery and reinfusion in surgery and trauma. Bethesda (MD): American Association of Blood Banks; 2010.
36. Ilstrup SJ, Dyga RM, Rios J, Berg MP, Puca KE, Spitzer AI, Vlahakes GJ, Shander A, Perelman S,. Standards for perioperative autologous blood collection and administration. 4th ed. Bethesda (MD): American Association of Blood Banks; 2009.
37. Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Tisherman SA, Hebert PC, Anderson GL, Bard MR, Bromberg W, Chiu WC, Cipolle MD, Clancy KD, Diebel L, Hoff WS, Hughes KM, Munshi I, Nayduch D, Sandhu R, Yelon JA,; American College of Critical Care Medicine of the Society of Critical Care Medicine. Clinical practice guidelines: red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009; 37: 3124-49.
38. Carson JL, Grossman B, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B,; for the Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012; 157: 49-58.
39. Tokin C, Almeda J, Jain S, Kim J, Henderson R, Nadim M, Sher L, Selby RR,. Blood-management programs: a clinical and administrative model with program implementation strategies. Permanente J 2009; 13: 18-28.
40. Gombotz H, Rehak P, Shander A, Hofmann A,. Blood use in elective surgery: the Austrian benchmark study. Transfusion 2007; 47: 1468-80.
41. Gombotz H, Rehak P, Shander A,. Blood use in elective surgery: the 2nd Austrian Benchmark Study. Austrian Federal Department of Health, 2011.
42. Freedman J, Luke K, Monga N, Lincoln S, Koen R, Escobar M, Chiavetta J,. A provincial program of blood conservation: the Ontario Transfusion Coordinators (ONTraC). Transfus Apher Sci 2005; 33: 343-9.
43. Helm RE, Rosengart TK, Gomez M, Klemperer JD, DeBois WJ, Velasco F, Gold JP, Altorki NK, Lang S, Thomas S, Isom OW, Krieger KH,. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998; 65: 125-36.
44. Green JA,. Blood conservation in cardiac surgery: the Virginia Commonwealth University (VCU) experience. J Cardiothorac Vasc Anesth 2004; 8 (Suppl 4): 18S-23S.
45. Moskowitz DM, McCullough JN, Shander A, Klein JJ, Bodian CA, Goldweit RS, Ergin MA,. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? Ann Thorac Surg 2010; 90: 451-8.
46. Kamel H, Tomasulo P, Bravo M, Wiltbank T, Cusick R, James RC, Custer B,. Delayed adverse reactions to blood donation. Transfusion 2010; 50: 556-65.
47. US Department of Health and Human Services. The 2009 national blood collection and utilization survey report. Washington, DC: DHHS, 2011.
48. Stohlawetz P, Stiegler G, Jilma B, Dettke M, Höcker P, Panzer S,. Measurement of the levels of reticulated platelets after plateletpheresis to monitor activity of thrombopoiesis. Transfusion 1998; 38: 454-8.
49. Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF,. Sustained decreases in platelet counts associated with multiple, regular plateletpheresis donations. Transfusion 2001; 41: 756-61.
50. Amrein K, Katsching C, Sipurzynski S, Stojakovic T, Lanzer G, Stach E, Pieber TR, Dobnig H,. Apheresis affects bone and mineral metabolism. Bone 2010; 46: 789-95.
51. Vamvakas EC,. A patient-centric approach to preventing allergic reactions to platelet transfusions. Transfusion 2011; 51: 1651-3.
52. FDA/CBER. Study Designs (Phases 3 and 4) for Product Development of Human Platelets Using the Cerus INTERCEPT Blood System for Pathogen Inactivation. Meeting of the Blood Products Advisory Committee: November 16. 2009: 158-345, [cited 2012 Jul 11]. Available from: URL: http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/BloodVaccinesOtherBiologics/ BloodProductAdvisoryCommittee/ucm189003.pdf
53. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P,. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44: 1774-89.
54. Popovsky MA, Moore SB,. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25: 573-7.
55. Welsby I, Troughton M, Phillips-Bute B, Ramsey R, Campbell ML, Bandarenko N, Mathew JP, Stafford-Smith M,; Cardiothoracic Anesthesiology Research Endeavors. The relationship of plasma transfusion from female and male donors with outcome after cardiac surgery. J Thorac Cardiovasc Surg 2010; 140: 1353-60.
56. Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, Glynn SA, Hillyer CD, Carey P, Gottschall JL, Murphy EL, Rios JA, Ness PM, Wright DJ, Carrick D, Schreiber GB,. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49: 1825-35.
57. Kleinman SH, Triulzi DJ, Murphy EL, Carey PM, Gottschall JL, Roback JD, Carrick D, Mathew S, Wright DJ, Cable R, Ness P, Gajic O, Hubmayr RD, Looney MR, Kakaiya RM,; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II. The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human-leukocyte-antigen antibody-positive or negative components. Transfusion 2011; 51: 1078-91.
58. van Stein D, Beckers EA, Sintnicolaas K, Porcelijn L, Danovic F, Wollersheim JA, Brand A, van Rhenen DJ,. Transfusion-related acute lung injury in the Netherlands: an observational study. Transfusion 2010; 50: 213-20.
59. Wiersum-Osselton JC, Middelburg RA, Beckers EA, van Tilborgh AJ, Zijlker-Jansen PY, Brand A, van der Bom JG, Schipperus MR,. Male-only fresh frozen plasma for transfusion-related acute lung injury prevention: before-and-after comparative cohort study. Transfusion 2011; 51: 1278-83.
60. Middelburg RA, le Cessie S, Briet E, Vandenbrouke JP, van der Born JG,. A solution to the problem of studying blood-donor-related risk factors when patients have received multiple transfusions. Transfusion 2010; 50: 1959-66.
61. Win N, Chapman CE, Bowles KM, Green A, Bradley S, Edmondson D, Wallis JP,. How much residual plasma may cause TRALI? Transfus Med 2008; 18: 276-80.
62. Chapman CE, Stainsby D, Jones D, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM,; Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of the preferential use of male donor plasma. Transfusion 2009; 49: 440-52.
63. Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ,. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007; 47: 599-607.
64. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP,. Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 1999; 340: 438-47.
65. Peden AH, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling M, Millar CM, Hill FG, Ironside JW,. Preclinical vCJD infection in the spleen of a neurologically asymptomatic UK adult patient with hemophilia. Haemophilia 2010; 16: 296-304.
66. Vamvakas EC,. Universal white-blood-cell reduction in Europe: has transmission of vCJD been prevented? Transf Med Rev 2011; 25: 133-44.
67. Cholan G, Llewelyn C, Mackenzie J, Cousens S, Kennedy A, Will R, Hewitt P,. Variant Creutzfeldt-Jacob disease in a transfusion recipient. Coincidence or cause? Transfusion 2010; 50: 1003-6.
68. Houston F, McCutcheon S, Goldman W, Chong A, Foster J, Sisõ S, González L, Jeffrey M, Hunter N,. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008; 112: 4739-45.
69. Dodd RY,. Emerging infections, transfusion safety, and epidemiology. N Engl J Med 2003; 349: 1205-6.
70. Foster KR, Vecchia P, Repacholi MH,. Science and the precautionary principle. Science 2000; 288: 979-81.
71. Wilson K, Wilson M, Hébert PC, Graham I,. The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy. Transf Med Rev 2003; 17: 89-94.
72. Commission of the European Communities. Communication on the Precautionary Principle, Brussels, Feb. 2000.
73. Turner ML, Ludlam CA,. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haem 2009; 144: 14-23.
74. Jakobs MR, Smith D, Heaton WA, Good CE,. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection Test. Transfusion 2011; 51: 2573-82.
75. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG,; SPRINT Study Group. Clinical safety of platelets photochemically-treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45: 1864-75.
76. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104: 1534-41.
77. Vamvakas EC,. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51: 1058-71.
78. Vamvakas EC,. Meta-analysis of studies of the bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012; 102: 302-16.
79. Edelstein LC, Bray PF,. MicroRNAs in platelet production and activation. Blood 2011; 117: 5289-96.
80. Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, Chen J, McKnight GS, Lõpez JA, Yang L, Jin Y, Bray MS, Leal SM, Dong JF, Bray PF,. Platelet microRNA-mRNA co-expression profiles correlate with platelet reactivity. Blood 2011; 117: 5189-97.
81. Hitzler W, Vamvakas EC,. Platelet microRNA profiles and the effect of pathogen reduction on platelet function. Clin Lab 2011; 57: 451-4.
82. Kerkhoffs JLH, van Putten WLJ, Novotny VMJ, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ,; Dutch-Belgian HOVON Cooperative Group. Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
83. Harris J,. QALYfying the value of life. J Med Ethics 1987; 13: 117-23.
84. AuBuchon JP, Birkmeyer JD, Busch MP,. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 1997; 37: 45-51.
85. Stowell CP, Jones SC, Enny C, Langholff W, Leitz G,. An open-label randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine 2009; 34: 2479-85.
86. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI,. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009; 101: 1633-41.
87. Lipp G, Franchini M, Favaloro EJ,. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 2010; 36: 537-49.
88. van der Meer P, Groenveld HF, Jannuzzi JL Jr, van Veldhuisen DJ,. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009; 95: 1309-14.
89. Isbister JP, Shander A, Spahn DR, Erhard J, Farmer SL, Hofmann A,. Adverse blood transfusion outcomes: establishing causation. Transf Med Rev 2011; 25: 89-101.
90. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH,. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358: 1229-39.
91. Kashuk J,. Post-injury life-threatening coagulopathy: is 1:1 FFP:RBCs the answer? J Trauma 2008; 65: 261-71.
92. Scalea TM, Bochicchio KM, Lumpkins K, Hess JR, Dutton R, Pyle A, Bochicchio GV,. Early aggressive use of fresh frozen plasma does not improve outcome in critically-injured trauma patients. Ann Surg 2008; 248: 578-84.
93. Snyder CW, Weinberg JA, McGwin G Jr, Melton SM, George RL, Reiff DA, Cross JM, Hubbard-Brown J, Rue LW 3rd, Kerby JD,. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma 2009; 66: 358-62.
94. Hannon T,. Trauma blood management: avoiding the collateral damage of trauma resuscitation protocols. Hematology Am Soc Hematol Educ Program 2010; 2010: 463-4.
95. Murad MH, Stubbs JR, Gandhi MJ, Wang AT, Paul A, Erwin PJ, Montori VM, Roback JD,. The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion 2010; 50: 1370-83.
96. Vamvakas EC, Blajchman MA,. Transfusion-related immunomodulation: an update. Blood Rev 2007; 21: 327-48.
97. Vamvakas EC,. Establishing causation in transfusion medicine and related tribulations. Transfus Med Rev 2011; 25: 81-8.
98. Vamvakas EC,. Paradigm shifts in transfusion medicine. In:, Vamvakas EC,. Decision making in transfusion medicine. Bethesda (MD): American Association of Blood Banks; 2011. p. 265-305.